The use of isoniazid as a marker to monitor the self-administration of medicaments.
1. Isoniazid was used as a marker to monitor the regularity of drug self-administration in a trial of chemoprophylaxis against natural influenza infection. Two hundred and sixty-two volunteers were treated for five weeks with a synthetic isoquinoline compound (U.K. 2371) or a matching placebo. 2. Five marker tablets containing isoniazid (150 mg) were incorporated into each regimen and their ingestion monitored by testing for acetylisoniazid in the urine. 3. Positive evidence of marker tablet consumption was obtained on 75% of the occasions on which urine samples were requested. The results obtained among the volunteers from each treatment group who returned urine specimens as requested (92%) indicated that they had swallowed at least 81% of their prescribed tablets. 4. The findings of the study suggest that when used in this way isoniazid is a very suitable compound for use on a few occasions for monitoring the self-administration of drugs in clinical trials.
D000293:Adolescent; D000328:Adult; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D004358:Drug Therapy; D006801:Humans; D007251:Influenza, Human / Q000517:prevention & control; D007538:Isoniazid / Q000652:urine; D007546:Isoquinolines / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D010349:Patient Compliance; D012646:Self Administration
D007546:Isoquinolines; D007538:Isoniazid